Results for tag: "Viral Hepatitis"

Within the context of infectious diseases drugs, the viral hepatitis market comprises the development, production, and sale of pharmaceuticals that specifically target various forms of the hepatitis virus, including hepatitis A, B, C, D, and E. Hepatitis is a liver disease characterized by the inflammation of the liver, caused by different viral pathogens that lead to a spectrum of health disorders, from mild to severe, including cirrhosis and liver cancer. As each type of hepatitis virus requires distinct therapeutic approaches, the market encapsulates a range of antiviral treatments, immunoglobulins, vaccines, and advanced therapies designed for eradication, management, and prevention of these diseases. The market is driven by research and innovation as pharmaceutical companies engage in the discovery of new drug formulations and treatment regimes, often collaborating with health organizations and researchers to address the therapeutic needs prompted by varying geographical prevalence and resistance profiles. Companies actively participating in the viral hepatitis market include Gilead Sciences, which has developed treatments for hepatitis C, and GlaxoSmithKline, known for its hepatitis vaccines. Other players include Merck & Co., which offers therapeutics and vaccines for hepatitis, and AbbVie, which also provides treatments for hepatitis C. These enterprises are joined by various biotechnology firms and generic drug manufacturers, all contributing to a diverse and dynamic sector within the infectious diseases pharmaceutical landscape. Show Less Read more